19.4 C
Seoul
Sunday, May 28, 2023
Home CEO Wealthy troublemakers

Wealthy troublemakers

This is where you can find detailed information about South Korean rich people, who were imprisoned or have gong through troubles related to drugs, alcohol, or gapjil (power harassment).

Illegal drug use of namyang founder's granddaughter This is the sixth of a series, which highlights Korea’s wealthy businesspeople who caused troubles related to drugs, alcohol, and power harassment called “gap-jil” here. _ ED. Namyang Dairy Products is one of the...
Hyundai founder's grandson got suspended jail term for drug use This is the fifth of a series, which highlights Korea’s wealthy businesspeople who caused troubles related to drugs, alcohol, and power harassment called “gap-jil” here. _ ED. Chung Ju-yung, a son...
SK founder's grandson got suspended jail term for drug use This is the fourth of a series, which highlights Korea’s wealthy businesspeople who caused troubles related to drugs, alcohol, and power harassment called “gap-jil” here. _ ED. SK Group is one...
Hanwha scion caused multiple troubles related to drugs, alcohol This is the third of a series, which highlights Korea’s wealthy businesspeople who caused troubles related to drugs, alcohol, and power harassment called “gap-jil” here. _ ED. Kim Dong-won is the second...
CJ Group heir apparent imprisoned in 2019 due to drug smuggling This is the second of a series, which highlights Korea’s wealthy businesspeople who caused troubles related to drugs, alcohol, and power harassment called “gapjil” here. _ ED. Born in 1990,...
From drugs to alcohol, and power harassment South Korea’s economy is dominated by chaebol, the sprawling conglomerates like Samsung and Hyundai where founding families exercise full control despite small direct shareholdings. As the ownership of such conglomerates has been transferred within...

POPULAR ARTICLES

LATEST ARTICLES

Celltrion's Humira biosimilar wins FDA approval

Celltrion’s Humira biosimilar gains FDA approval

Yuflyma strives to tap into the U.S. market South Korean pharmaceutical company Celltrion said on May 25 that its Humira biosimilar CT-P17, or Yuflyma, had...